Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine for prevention of COVID-19 after close contact exposure
IRCT20190122042450N4Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of hydroxychloroquine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Iran University of Medical Sciences. Primary endpoints: Reducing the incidence of COVID-19, Reducing hospitalization time in medical center and 2 more. Started Apr 2020; status: completed.
02
Drugs
hydroxychloroquine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20190122042450N4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190122042450N4.